Pharmaceutical Stock Flies Higher on Drug Announcement

the only analyst in coverage carries a "buy" rating

Deputy Editor
Jun 19, 2020 at 11:28 AM
facebook twitter linkedin

The shares of Australian biopharmaceutical company Immuron Limited (NASDAQ:IMRN) are up 40.8% at $10.91 at last check, after announcing plans to create a diarrhea drug for evaluation by the U.S. Defense Department. The drug will be produced by CSIRO using vaccines developed by the U.S. Naval Medical Research Center, and the Naval Medical research center plans to submit a pre-investigational new drug (IND) information package to the U.S. Food and Drug Administration (FDA). 

IMRN has fallen far below its recent all-time high of $28.99 on June 9. Now a chip-shot away from its support at the 10-day moving average, the equity is climbing on the charts once again, up a whopping 504% in the last three months alone. It's also worth noting that trading was halted today due to the stock's massive swing in volatility. 

The lone analyst in coverage carries a "buy" rating. Meanwhile, the 12-month consensus price target of $6 is a 44.7% discount to current levels. 




If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners